Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.440
-0.170 (-10.56%)
Mar 6, 2026, 10:54 AM EST - Market open
Metagenomi Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 25.21 | 52.3 | 44.76 | 17.2 | 0.24 |
| Revenue Growth (YoY) | -51.79% | 16.84% | 160.21% | 6978.19% | - |
| Cost of Revenue | - | 109.18 | 94.4 | 43.14 | 14.48 |
| Gross Profit | 25.21 | -56.88 | -49.65 | -25.94 | -14.24 |
| Selling, General & Admin | 26.79 | 32.02 | 28.85 | 18.7 | 9.71 |
| Research & Development | 94.43 | - | - | - | - |
| Operating Expenses | 121.22 | 32.02 | 28.85 | 18.7 | 9.71 |
| Operating Income | -96.01 | -88.9 | -78.49 | -44.64 | -23.95 |
| Interest Expense | - | - | - | -0.1 | -0.3 |
| Interest & Investment Income | 9.47 | 14.72 | 15.47 | 3.42 | 0.04 |
| Other Non Operating Income (Expenses) | -0.09 | -0.21 | -0.07 | 0.2 | 0 |
| EBT Excluding Unusual Items | -86.63 | -74.39 | -63.1 | -41.12 | -24.2 |
| Gain (Loss) on Sale of Investments | -1.29 | -9.19 | 2.87 | 0.09 | 2.76 |
| Pretax Income | -87.93 | -83.57 | -60.23 | -41.02 | -21.44 |
| Income Tax Expense | -0.06 | -5.51 | 8.03 | 2.57 | - |
| Net Income | -87.87 | -78.06 | -68.26 | -43.59 | -21.44 |
| Net Income to Common | -87.87 | -78.06 | -68.26 | -43.59 | -21.44 |
| Shares Outstanding (Basic) | 37 | 33 | 3 | 3 | 6 |
| Shares Outstanding (Diluted) | 37 | 33 | 3 | 3 | 6 |
| Shares Change (YoY) | 12.79% | 870.10% | 0.15% | -40.27% | - |
| EPS (Basic) | -2.36 | -2.36 | -20.05 | -12.82 | -3.77 |
| EPS (Diluted) | -2.36 | -2.36 | -20.05 | -12.82 | -3.77 |
| Free Cash Flow | -89.47 | -112.19 | -101.22 | 15.75 | 21.35 |
| Free Cash Flow Per Share | -2.40 | -3.40 | -29.73 | 4.63 | 3.75 |
| Gross Margin | 100.00% | -108.78% | -110.93% | -150.81% | - |
| Operating Margin | -380.85% | -170.00% | -175.38% | -259.53% | -9854.73% |
| Profit Margin | -348.54% | -149.27% | -152.50% | -253.45% | -8823.87% |
| Free Cash Flow Margin | -354.88% | -214.53% | -226.17% | 91.55% | 8787.65% |
| EBITDA | -90.7 | -83.49 | -74.29 | -42.91 | -23.56 |
| EBITDA Margin | - | -159.66% | -165.98% | -249.46% | - |
| D&A For EBITDA | 5.32 | 5.41 | 4.21 | 1.73 | 0.39 |
| EBIT | -96.01 | -88.9 | -78.49 | -44.64 | -23.95 |
| EBIT Margin | - | -170.00% | -175.38% | -259.53% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.